Navigation Links
Reportlinker Adds Cancer Vaccines Markets
Date:4/26/2011

NEW YORK, April 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Vaccines Markets

http://www.reportlinker.com/p0486610/Cancer-Vaccines-Markets.html

Cancer vaccines have the potential to become a significant force in future cancer treatments. In 2010, Dendreon's Provenge became the first cancer vaccine approved by the FDA, generating renewed interest and support for this type of cancer immune therapy. Cancer vaccines can be divided into six main categories: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. This relatively new commercial market for cancer vaccines is poised to dramatically increase to over $7 billion by 2015. The purpose of this TriMark Publications report is to supply comprehensive information on the developing market for cancer vaccines. This study surveys almost all of the companies known to be marketing, manufacturing, or developing cancer vaccines in the world, providing in-depth analysis of the current and emerging technologies in the cancer vaccines market. Each company is extensively examined, with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Moreover, this report provides detailed discussions of cancer vaccines funding trends, intellectual property, market opportunities, research collaborations, partnership activities, regulatory issues and guidelines for establishing new ventures. Detailed tables and charts with sales forecasts and market share data are also included.

TABLE OF CONTENTS

1. Overview 5

1.1 About this Report 5

1.2 Scope of the Report 6

1.3 Objectives 6

1.4 Methodology 6

1.5 Executive Summary 7

2. Overview of Cancer 9

2.1 Cancer Statistics 9

2.2 The Cost of Cancer 13

2.3 Cancers Being Targeted by Vaccine Therapies: Overview of Disease and Market

16

3. Introduction to Cancer Vaccines 24

3.1 Overview of the Types of Cancer Vaccines 24

3.2 Antigen/Adjuvant Vaccines 27

3.3 DNA Vaccines 33

3.4 Vector-based Vaccines 35

3.5 Tumor Cell Vaccines 35

3.6 Dendritic Cell (DC) Vaccines 37

3.7 Anti-Idiotype Vaccines 38

4. Prophylactic Vaccines on the Market and in Development 40

4.1 Cervical Cancer (HPV) 40

4.2 Prophylactic Breast Cancer Vaccine in Development 42

5. Therapeutic Vaccines on the Market and in Development 43

5.1 Breakthroughs in the Cancer Vaccine Market: Vaccines on the Market 43

5.2 Vaccines in Development (by Type of Vaccine) 45

6. Challenges and Issues in Cancer Vaccine Development 74

6.1 Eliciting Appropriate Immune Response Against Cancer 74

6.2 Clinical Trial Design 78

6.3 Combination Therapies 82

7. Regulatory Issues 84

7.1 Pharmaceutical Product Regulation 84

7.2 New Drug Application (NDA) or Biologics License Application (BLA) 86

7.3 Post-Approval Phase 86

7.4 Fast-Track Review 87

7.5 Orphan Drug Designation and Exclusivity 88

7.6 What Regulatory Guidance Is Needed for Companion Biomarkers? 88

7.7 Oncology Biomarker Qualification Initiative 89

7.8 IRB Approval in Clinical Trials 89

7.9 U.S. Patent and Trademark Office (USPTO) 89

8. Trends Affecting the Cancer Vaccine Market 90

8.1 Screening and Cancer Detection 90

8.2 Public Perception of Vaccines 90

8.3 Insurance Issues 91

8.4 New Technological and Scientific Developments 91

8.5 Personalized Medicine 91

9. Business Landscape 93

9.1 Technology and Market Trends 93

9.2 M&A Activity 94

9.3 Partnering 94

9.4 Competitive Situation 96

9.5 Intellectual Property Rights 97

9.6 Industry Challenges and Strategic Recommendations for Commercialization 98

9.7 Opportunities and Strategic Recommendations 99

9.8 Requirements for a Successful Cancer Vaccine Products Industry 102

10. Company Profiles 106

10.1 Advaxis 106

10.2 Agenus (formerly Antigenics) 106

10.3 AlphaVax 106

10.4 Antigen Express 107

10.5 Apthera 107

10.6 Argos Therapeutics 107

10.7 AVAX Technologies 107

10.8 Bavarian Nordic 108

10.9 Bellicum Pharmaceuticals 108

10.10 BioSante Pharmaceuticals 108

10.11 Biovest International 108

10.12 Celldex Therapeutics 109

10.13 CG Therapeutics 109

10.14 CureVac 109

10.15 DanDrit Biotech 109

10.16 Dendreon 110

10.17 EMD Serono 110

10.18 Geron 110

10.19 GlaxoSmithKline 110

10.20 GlobeImmune 111

10.21 Immatics Biotechnologies 111

10.22 ImmunoCellular Therapeutics 111

10.23 Immunovaccine 111

10.24 Inovio Pharmaceuticals 111

10.25 KAEL-Gemvax 112

10.26 MannKind 112

10.27 Mologen AG 112

10.28 NewLink Genetics Corporation 112

10.29 Northwest Biotherapeutics 113

10.30 NovaRx 113

10.31 Oxford BioMedica 113

10.32 Prima BioMed 113

10.33 Scancell 113

10.34 Transgene 113

10.35 Trimed Biotech 114

10.36 Vaccinogen 114

10.37 Vical 114

INDEX OF FIGURES

Figure 2.1: Estimates of National Expenditures for Cancer Care in 2006 by Cancer

Site 14

Figure 2.2: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Male,

2006 15

Figure 2.3: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Female,

2006 16

Figure 3.1: Antigen Presentation 25

Figure 3.2: Antigen/Adjuvant Cancer Vaccine Immunotherapy Process 27

Figure 3.3: DNA Cancer Vaccine Immunotherapy Process 34

Figure 3.4: Viral Vector Cancer Vaccine Immunotherapy Process 35

Figure 3.5: Modified Tumor Cell Cancer Vaccines 37

Figure 3.6: Dendritic Cell Vaccination Process 38

Figure 3.7: Schematic of Anti-idiotype Antibodies for Cancer Vaccines 39

Figure 5.1: New Therapeutic Cancer Vaccines Entering Clinical Study Per Year

During 1990-2006 46

INDEX OF TABLES

Table 2.1: Estimated New Cancer Cases and Deaths in the U.S. by Sex for all

Cancer Sites, 2010 9

Table 2.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in

the U.S. in 2010, by Sex 11

Table 2.3: Worldwide Number of New Cancer Cases and Deaths by Leading Cancer

Sites and by Level of Economic Development, 2008 12

Table 2.4: Number of New Cancer Cases and Deaths by World Area, 2008 13

Table 2.5: Estimated Annual Costs of Cancer in the U.S. in Billions, 2008 14

Table 2.6: Cancer Vaccines in the Pipeline, by Cancer Type 17

Table 3.1: Infectious Agents Involved in Cancer 24

Table 3.2: Cancer Vaccine Technologies 26

Table 3.3: Antigens Commonly Found in Cancer Vaccines 29

Table 3.4: Adjuvants Commonly Found in Cancer Vaccines 31

Table 4.1: Cervical Cancer Vaccines on the Market 41

Table 5.1: Therapeutic Vaccines on the Market 44

Table 5.2: Pipeline of Therapeutic Cancer Vaccines, by Type of Vaccine 46

Table 5.3: Antigen/Adjuvant Vaccines in Development 48

Table 5.4: DNA and RNA Vaccines in Development 55

Table 5.5: Vector-based Vaccines in Development 58

Table 5.6: Autologous Tumor Cell Vaccines in Development 62

Table 5.7: Allogeneic Tumor Cell Vaccines in Development 64

Table 5.8: Dendritic Cell Vaccines in Development 66

Table 5.9: Anti-Idiotype Vaccines in Development 69

Table 5.10: Competitors with Phase III Cancer Vaccine Candidates in Their

Pipelines 71

Table 6.1: Mechanisms of Immune Evasion by Cancers 77

Table 6.2: Key Recommendations for Cancer Vaccine Clinical Trial Design 78

Table 6.3: Challenges and Strategic Recommendations for Clinical Trial Design 79

Table 6.4 Combination Strategies to Enhance a Vaccine's Anti-Tumor T-Cell

Response 82

Table 7.1: Focus Areas for the FDA Critical Path Initiative 89

Table 9.1: Industry Challenges and Strategic Recommendations for

Commercialization 98

Table 9.2: Required Elements of a Manufacturing Facility 103

Table 9.3: CMO Qualification Audit-Points to Investigate 104

Table 9.4: Strategies for Marketing Cancer Vaccines 105

To order this report:

: Cancer Vaccines Markets

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced ... Food and Drug Administration (FDA) on February 4, 2016, ... on the clinical studies being conducted under the Company,s ... hold impacts part of the clinical work currently being ... clinical trials. --> ...
(Date:2/5/2016)... 2016  Despite the recent explosion in Big Data, ... to embrace Big Data due to the inherent costs ... side, organizations have begun looking to Big Data as ... adherence. --> --> ... LLC, Big Data has started informing many decisions. In ...
(Date:2/5/2016)... -- Redwood Scientific Technologies, Inc. announced today the development and ... balance their hormones. This product will be featuring Redwood,s ... Cardiff , President and CEO. "I am proud that ... of women across the country and around the world ... research and development team is confident that through the ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... If you are feeling that your ... are not alone. According to the Center for Disease Control and Prevention (CDC), 34.9% ... diabetes and certain types of cancer, some of the leading causes of preventable death. ...
(Date:2/8/2016)... ... February 08, 2016 , ... Steve Helwig & Associates Insurance & ... community enrichment program, has teamed up with Citizens Opposed to Domestic Abuse in support ... abuse. To support all those victimized by the fear of violence in their own ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... serving the greater Venice, FL area, has initiated a fundraiser for a two ... accident just four days after Christmas. To support this beautiful child who is ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... firm, announced today that nominations will be accepted February 8, 2016 through ... , Awards include the Information Security Executive® of the Year, which ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders and post-traumatic stress ... women and men with eating disorders report a history of trauma, research suggests ... of an eating disorder. , At the 2016 iaedp Symposium, the workshop, ...
Breaking Medicine News(10 mins):